Cytek Biosciences, Inc. (CTKB)

From the record

Cytek Biosciences, Inc.'s filings since 2020 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2024-03-01) (its current reports).

From the record

Cytek Biosciences, Inc.'s 6 filed years say what it did: revenue went from $93 million in fiscal 2020 to $201 million in fiscal 2025, up 16.8% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 3 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Cytek Biosciences, Inc.'s diluted share count shrank about 2.7% a year, and dividends and buybacks returned about 100% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Cytek Biosciences, Inc. lost about 19 cents for every dollar of shareholders' money, and gross profitability: its products earned about 23 cents per dollar of everything the company owns. Leverage: it owed about 26 cents per dollar of assets, and net share issuance: its share count shrank 2.2% over the year (the filed statements).

From the record

Cytek Biosciences, Inc.'s standing among 21 graded names in its industry family: revenue of $201 million in fiscal 2025 ranks in the top 45% by size; a net margin of -33% ranks in the top 50%; revenue growth of 7.1% a year over the last 3 filed years ranks in the top 32% (its annual reports).

From the record

Cytek Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Jiang, Wenbin (PRESIDENT AND CEO, as filed), filing under that title since 2021-07-22, 5.3 years (top 50% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 3.8 years (bottom 40%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Cytek Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $91 million against no long-term debt tagged leaves 19.7% of its assets as net cash, top 30% of its family; cash from operations less capital spending is -4.4% of revenue (bottom 45%); a gross margin of 51.8% (top 42%); research spending of 18.1% of revenue (bottom 43%) (its annual report).

From the record

Cytek Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 7.1% a year over the last three filed years against 16.8% over all 6, slowing (bottom 38% of its family); the newest year grew 0.5% (bottom 36%); research spending grew 1.5% a year (top 47%); capital spending grew -25.2% a year (bottom 33%) (its annual reports). Cytek Biosciences, Inc. reported 2 product lines in fiscal 2025: Product at $144 million (72%), Service at $57 million (28%); 1 of 2 grew against the year before (its annual report).

From the record

Cytek Biosciences, Inc.'s newest year against its own record: revenue of $201 million in fiscal 2025 came in 9.1% below the $222 million its prior three years' pace pointed to (bottom 28% of its family); net income of $67 million against a prior three-year average of $5 million (bottom 5%); a net margin of -33% against -2.6% before (bottom 23%) (its annual reports).